NCT00020267

Who might be able to join this trial:

• You have been diagnosed with one of these cancers that has spread to other parts of the body: skin melanoma, eye melanoma, colorectal cancer, non-small cell lung cancer, breast cancer, or sarcoma
• Your tissue has tested positive for a specific genetic marker called HLA-Cw*0702
• Your tissue shows expression of a protein called MAGE-12 (detected through a lab test on your tissue sample)
• Previous standard treatments for your cancer have not worked
• Your cancer can be measured or detected through scans or tests
• You are 16 years of age or older
• You are well enough to carry out light daily activities (a doctor will assess this)
• You are expected to live longer than 3 months
• Your blood cell counts and blood test results are within acceptable ranges (a doctor will check this)
• At least 3 weeks have passed since your last cancer treatment (biological therapy, chemotherapy, radiation, or hormone therapy) and you have recovered from its effects
• Previous surgery for cancer is acceptable

Who may not be able to join:

• You have kidney (renal) cancer
• You are currently receiving any other cancer treatments, including chemotherapy, hormone therapy, radiation therapy, or biological therapy
• You are currently taking steroid medications
• You are pregnant or breastfeeding, or unwilling to use contraception if you are able to have children
• You have an active infection in your body
• You have an autoimmune disease, a known immune system disorder, or an active immune deficiency condition
• You have tested positive for Hepatitis B or HIV
• You have significant heart problems such as reduced blood flow to the heart, a history of heart attack, or irregular heartbeat — particularly if you would be receiving a treatment called interleukin-2 (IL-2) (confirm with trial site)
• You have significant breathing or lung problems — particularly if you would be receiving IL-2 therapy (confirm with trial site)
• You have other serious active medical conditions — particularly if you would be receiving IL-2 therapy (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.